KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials
Authors:
- 22 April 2025
- journal article
- clinical trial-protocol
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 211, 104741
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 updateAnnals of Oncology, 2025
- KRAS inhibitors: resistance drivers and combinatorial strategiesTrends in Cancer, 2024
- Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLCTargeted Oncology, 2024
- Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living GuidelineAnnals of Oncology, 2023
- KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testingLung Cancer, 2023
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyThe Lancet, 2023
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013